These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 25175149)

  • 1. Induction of fibronectin in response to epidermal growth factor is suppressed by silibinin through the inhibition of STAT3 in triple negative breast cancer cells.
    Kim S; Jeon M; Lee J; Han J; Oh SJ; Jung T; Nam SJ; Kil WH; Lee JE
    Oncol Rep; 2014 Nov; 32(5):2230-6. PubMed ID: 25175149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silibinin inhibits triple negative breast cancer cell motility by suppressing TGF-β2 expression.
    Kim S; Han J; Jeon M; You D; Lee J; Kim HJ; Bae S; Nam SJ; Lee JE
    Tumour Biol; 2016 Aug; 37(8):11397-407. PubMed ID: 26984157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
    Kim S; Lee J; Jeon M; Lee JE; Nam SJ
    Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
    Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
    Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silibinin suppresses EGFR ligand-induced CD44 expression through inhibition of EGFR activity in breast cancer cells.
    Kim S; Han J; Kim JS; Kim JH; Choe JH; Yang JH; Nam SJ; Lee JE
    Anticancer Res; 2011 Nov; 31(11):3767-73. PubMed ID: 22110198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silibinin downregulates MMP2 expression via Jak2/STAT3 pathway and inhibits the migration and invasive potential in MDA-MB-231 cells.
    Byun HJ; Darvin P; Kang DY; Sp N; Joung YH; Park JH; Kim SJ; Yang YM
    Oncol Rep; 2017 Jun; 37(6):3270-3278. PubMed ID: 28440514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of fibronectin by HER2 overexpression triggers adhesion and invasion of breast cancer cells.
    Jeon M; Lee J; Nam SJ; Shin I; Lee JE; Kim S
    Exp Cell Res; 2015 Apr; 333(1):116-26. PubMed ID: 25743092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effect of silibinin on EGFR signal-induced renal cell carcinoma progression via suppression of the EGFR/MMP-9 signaling pathway.
    Liang L; Li L; Zeng J; Gao Y; Chen YL; Wang ZQ; Wang XY; Chang LS; He D
    Oncol Rep; 2012 Sep; 28(3):999-1005. PubMed ID: 22736024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silibinin induces cell death through reactive oxygen species-dependent downregulation of notch-1/ERK/Akt signaling in human breast cancer cells.
    Kim TH; Woo JS; Kim YK; Kim KH
    J Pharmacol Exp Ther; 2014 May; 349(2):268-78. PubMed ID: 24472723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells.
    Merrouche Y; Fabre J; Cure H; Garbar C; Fuselier C; Bastid J; Antonicelli F; Al-Daccak R; Bensussan A; Giustiniani J
    Oncotarget; 2016 Aug; 7(33):53350-53361. PubMed ID: 27462789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells.
    Cufí S; Bonavia R; Vazquez-Martin A; Corominas-Faja B; Oliveras-Ferraros C; Cuyàs E; Martin-Castillo B; Barrajón-Catalán E; Visa J; Segura-Carretero A; Bosch-Barrera J; Joven J; Micol V; Menendez JA
    Food Chem Toxicol; 2013 Oct; 60():360-8. PubMed ID: 23916468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiotoxin III suppresses MDA-MB-231 cell metastasis through the inhibition of EGF/EGFR-mediated signaling pathway.
    Tsai PC; Hsieh CY; Chiu CC; Wang CK; Chang LS; Lin SR
    Toxicon; 2012 Oct; 60(5):734-43. PubMed ID: 22683533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The scaffolding protein NHERF1 sensitizes EGFR-dependent tumor growth, motility and invadopodia function to gefitinib treatment in breast cancer cells.
    Bellizzi A; Greco MR; Rubino R; Paradiso A; Forciniti S; Zeeberg K; Cardone RA; Reshkin SJ
    Int J Oncol; 2015 Mar; 46(3):1214-24. PubMed ID: 25530180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.
    Shapira I; Lee A; Vora R; Budman DR
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):284-92. PubMed ID: 23755891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy.
    Bosch-Barrera J; Menendez JA
    Cancer Treat Rev; 2015 Jun; 41(6):540-6. PubMed ID: 25944486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zerumbone suppresses EGF-induced CD44 expression through the inhibition of STAT3 in breast cancer cells.
    Kim S; Kil WH; Lee J; Oh SJ; Han J; Jeon M; Jung T; Lee SK; Bae SY; Lee HC; Lee JH; Yi HW; Kim SW; Nam SJ; Lee JE
    Oncol Rep; 2014 Dec; 32(6):2666-72. PubMed ID: 25269647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silibinin prevents TPA-induced MMP-9 expression and VEGF secretion by inactivation of the Raf/MEK/ERK pathway in MCF-7 human breast cancer cells.
    Kim S; Choi JH; Lim HI; Lee SK; Kim WW; Kim JS; Kim JH; Choe JH; Yang JH; Nam SJ; Lee JE
    Phytomedicine; 2009 Jun; 16(6-7):573-80. PubMed ID: 19181503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
    Kim EM; Mueller K; Gartner E; Boerner J
    J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular hierarchy of heparin-binding EGF-like growth factor-regulated angiogenesis in triple-negative breast cancer.
    Yotsumoto F; Tokunaga E; Oki E; Maehara Y; Yamada H; Nakajima K; Nam SO; Miyata K; Koyanagi M; Doi K; Shirasawa S; Kuroki M; Miyamoto S
    Mol Cancer Res; 2013 May; 11(5):506-17. PubMed ID: 23443317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells.
    Song JY; Lee SW; Hong JP; Chang SE; Choe H; Choi J
    Cancer Lett; 2009 Oct; 283(2):135-42. PubMed ID: 19380191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.